How should diabetic hypoglycemia be treated? At present, hypoglycemia as a serious complication is often neglected in the treatment of diabetes. Patients appear sweating, hunger, weakness, pale complexion, limb shaking, palpitation and so on. When the blood glucose is lower than 2.8mmol/l, it will also cause central nervous depression and brain dysfunction, resulting in dizziness, drowsiness, unclear speech and blurred vision, resulting in abnormal behavior, unconsciousness, coma, convulsion and even death.
Professor Mu Yiming, deputy director of the endocrinology branch of the Chinese Medical Association and director of Department of Endocrinology, General Hospital of the PLA, today reminded diabetic patients that they should be alert to the risk of hypoglycemia and avoid hypoglycemia as far as possible.
He held a seminar on hypoglycemic control and prevention in diabetics here, emphasizing that patients with diabetes should not exercise when insulin or oral hypoglycemic agents are most effective. They should exercise as much as half an hour to one hour after meals. In addition, don't exercise on an empty stomach, and don't take a hot bath or take a sauna after exercise. Exercise will make the blood sugar drop quickly. If you take a hot bath or take a sauna again, the blood circulation will speed up and the blood sugar will decrease. He suggested that patients regularly monitor blood glucose levels, and continuous blood glucose monitoring can be carried out if conditions permit.
The mother teacher said that in order to avoid hypoglycemia, patients should choose the basic insulin treatment scheme in line with the physiological insulin secretion mode, that is, basic insulin plus oral medication or meal insulin. He believes that the ideal basic insulin should be able to simulate the physiological insulin secretion of normal people, and the effect is stable and sustainable for 24 hours, with a low probability of hypoglycemia. He revealed that at present, China has introduced long-acting human insulin analogues, which provides a new choice to reduce hypoglycemia caused by peak value of traditional insulin; The drug will enter the Beijing medical insurance drug catalogue on July 1 this year.